Has David Saperstein, MD received payments from drug or device companies?

Yes. Drug and device makers reported $54,266 in general payments to David Saperstein, MD across 89 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean David Saperstein, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about David Saperstein, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

David Saperstein, MD

Ophthalmology · Bellevue, WANPI 1508946625

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $51,033 of the $54,266 with a category attached, or 94.0%. Regeneron Healthcare Solutions, Inc. accounts for 86.9% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2024 at $23,313 and has fallen 81.5% since, to $4,302 in 2025. Among ophthalmology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$54,266in general payments, 2019–2025

Across 89 payments — averaging $609.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Regeneron Healthcare Solutions, Inc.$47K
Apellis Pharmaceuticals, Inc.$5K
Eyepoint US, Inc.$1K
Genentech USA, Inc.$206
Alcon Research LLC$182
Dutch Ophthalmic, USA$159
plus $559 from 9 others

$180,958in research payments, 2019–2025

Across 68 payments — averaging $2661.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Apellis Pharmaceuticals, Inc.$160K
Astellas Pharma Global Development$21K

What the payments were for

Consulting fees$51,03394%
Food & beverage$3,2346%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Regeneron Healthcare Solutions, Inc.	51	$47,180
Apellis Pharmaceuticals, Inc.	6	$4,570
Eyepoint US, Inc.	2	$1,410
Genentech USA, Inc.	9	$206
Alcon Research LLC	1	$182
Dutch Ophthalmic, USA	1	$159
Alcon	6	$150
AbbVie	3	$123
Genentech, Inc.	1	$88
Astellas Pharma US Inc	3	$71
Bausch & Lomb Americas Inc.	2	$36
Novartis	1	$32
Alimera Sciences, Inc.	1	$21
Regeneron	1	$21
Coherus Oncology, Inc.	1	$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$54,266 in reported general payments places this provider in the 95th percentile of 428 ophthalmology providers in Washington.

See all ophthalmology providers in Washington →

Medicare billing

Part B allowed, 2024

$4,928,935

Medicare patients

796

Services billed

32,003

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Prednisolone Acetate	130	$4,038
Difluprednate	36	$1,891
Ofloxacin	97	$1,091
Acetazolamide	13	$682
Ketorolac Tromethamine	14	$288
Latanoprost	54	$284
Brimonidine Tartrate	34	$174
Timolol Maleate	20	$117

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Bellevue

Audrey RostovBellevue$155K
Howard BarnebeyBellevue$53K
Mary CodayBellevue$10K
Stephanie HsuBellevue$6K
Laura PerimanSeattle$1.7M
Sheldon CowenSeattle$560K
Todd SchneidermanSilverdale$200K
Jennifer ChaoSeattle$188K
Mark KontosSpokane Valley$175K
John SamplesOlympia$115K

See the full list for Washington →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →